Reply: Adoption of Antifibrotic Medications: A Closer Look at the Data
- PMID: 33979273
- PMCID: PMC8522302
- DOI: 10.1513/AnnalsATS.202104-516LE
Reply: Adoption of Antifibrotic Medications: A Closer Look at the Data
Comment on
-
Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis.Ann Am Thorac Soc. 2021 Jul;18(7):1121-1128. doi: 10.1513/AnnalsATS.202007-901OC. Ann Am Thorac Soc. 2021. PMID: 33465323
-
Adoption of Antifibrotic Medications: A Closer Look at the Data.Ann Am Thorac Soc. 2021 Oct;18(10):1756-1757. doi: 10.1513/AnnalsATS.202103-359LE. Ann Am Thorac Soc. 2021. PMID: 33979262 Free PMC article. No abstract available.
References
-
- Dempsey TM, Payne S, Sangaralingham L, Yao X, Shah ND, Limper AH. Adoption of the anti-fibrotic medications pirfenidone and nintedanib for patients with idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2021 - PubMed
-
- Holtze CH, Freiheit EA, Limb SL, Stauffer JL, Raimundo K, Pan WT, et al. Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry. Respir Res. 2020;21:48. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
